Amneal Reports Third Quarter 2025 Financial Results

Core Insights - Amneal Pharmaceuticals reported a strong Q3 2025 with net revenue of $785 million, a 12% increase from $702 million in Q3 2024, and a GAAP net income of $2 million compared to a net loss of $0.2 million in the same quarter last year [1][3][4]. Financial Performance - Q3 2025 Adjusted EBITDA was $160 million, reflecting a 1% increase from the previous year, driven by higher revenue and gross profit, despite increased commercial investments [5]. - Adjusted diluted earnings per share (EPS) for Q3 2025 was $0.17, a 6% increase from $0.16 in Q3 2024, while diluted income per share was $0.01 compared to a diluted loss per share of $0.00 in Q3 2024 [6][4]. Business Segments - Specialty net revenue increased by 8%, driven by key branded products such as CREXONT® and UNITHROID®, while Affordable Medicines net revenue also rose by 8% due to strong performance in complex products and new launches [3][2]. - AvKARE net revenue surged by 24%, attributed to growth in government label sales [3]. Updated Guidance - The company updated its full-year 2025 guidance, maintaining net revenue expectations at $3.0 billion to $3.1 billion, while adjusting the adjusted EBITDA guidance to $675 million to $685 million, up from the previous range of $665 million to $685 million [8]. - Adjusted diluted EPS guidance was raised to $0.75 to $0.80 from $0.70 to $0.75, and operating cash flow guidance was increased to $300 million to $330 million from $275 million to $305 million [8]. Strategic Developments - The launch of BREKIYA® for migraines and the ongoing evolution of the product portfolio are expected to drive future growth [2]. - The company is entering a significant new product launch cycle in its Affordable Medicines segment, with multiple complex approvals and key launches anticipated [2].